This was a randomized , double-blind , parallel-group trial comparing 2.5 / 1.5 mg of NOMAC/E2 ( therapeutic dose ) , 12.5 / 7.5 mg of NOMAC/E2 ( supratherapeutic dose ) , placebo , and moxifloxacin 400 mg .